TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2430512
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy with nalidixic acid
Study: 2430512
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy with trimethoprim/sulphamethoxazole
Study: 2430512
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment (3-day)
Study: 2430512
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (10-day)
Study: 31122495
Drug: BIIB092 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB092 150 mg
Study: 31122495
Drug: BIIB092 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB092 700 mg
Study: 31122495
Drug: BIIB092 2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB092 2100 mg
Study: 26494856
Drug: High-dose FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FOLFIRI plus bevacizumab (every 2 weeks) in group 1 (UGT1A1 *1/*1)
Study: 26494856
Drug: High-dose FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FOLFIRI plus bevacizumab (every 2 weeks) in group 2 (UGT1A1 *1/*28)
Study: 26494856
Drug: High-dose FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FOLFIRI plus bevacizumab (overall population)
Study: 24494468
Drug: Restrictive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive group (RG) with low range of ITBVI (600‐800 ml/m2)
Study: 24494468
Drug: Liberal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal group (LG) with normal ITBVI (800‐1000 ml/m2)
Study: 20209995
Drug: Unbalanced crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbalanced crystalloid solution
Study: 7525694
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy (recombinant interferon-alpha 2a)
Study: 3593452
Drug: Zotepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (100 mg)
Study: 3593452
Drug: Moclobemide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (200 mg)
Study: 29508020
Drug: Venoplant tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoplant tablets and Venoplant gel
Study: 29508020
Drug: Only Venoplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only Venoplant tablets
Study: 20211002
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 microg once-daily
Study: 18596108
Drug: l‐NMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA
Study: 27811949
Drug: Intraileal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraileal protein infusion (15 g over 60 min)
Study: 27811949
Drug: Intraileal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraileal protein infusion
Study: 27811949
Drug: Intraduodenal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal protein infusion
Study: 27811949
Drug: Jejunal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal protein infusion
Study: 21824950
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone tablets, 200 mg daily
Study: 15612958
Drug: Extrathoracic expiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrathoracic expiratory resistance (EER; 0.89 kPa/L s at a flow of 0.5 L/s)
Study: 9550501
Drug: Aggressive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid-lowering therapy with statins
Study: 31236643
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (900 mg CF)
Study: 31236643
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 mg CF)
Study: 26556082
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group + visual spatial attention (optokinetic stimulation and right half‐field eye patching)
Study: 26556082
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (only conventional rehabilitation training)
Study: 1269192
Drug: Intravenous acebutolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acebutolol (1 mg/kg)
Study: 1269192
Drug: Oral acebutolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acebutolol (3 X 100 mg)
Study: 1269192
Drug: Renal clearance
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal clearance of acebutolol (after intravenous dosing)
Study: 18813941
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate electrolyte solution (CHO)
Study: 16542576
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg, q12 h) before catheterization
Study: 16542576
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH 25 mg intravenously before coronary angiography, additional 65 mg if PCI performed)
Study: 14499421
Drug: Intravenous adenosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adenosine, 2 mg
Study: 9314644
Drug: 30/70 IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/70 IA (insulin aspart)
Study: 9314644
Drug: 30/70 HI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/70 HI (human insulin)
Study: 1549026
Drug: Liquid glucose
Normalized name: Liquid glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid glucose (G)
Study: 7523736
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management with palliative therapy reserved for symptomatic or metastatic disease progression
Study: 28107894
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate variability biofeedback therapy (HRV-BF)
Study: 25160533
Drug: Lutein 10
Normalized name: lutein 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 10 mg daily for 1 year
Study: 18420965
Drug: Recent inhaled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent inhaled corticosteroid usage
Study: 1758385
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIG, 500 mg/kg Sandoglobulin)
Study: 31881702
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of walnuts per day
Study: 28917947
Drug: High glycemic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glycemic load meal + caffeine capsules (3mgkg‐1 body weight)
Study: 28917947
Drug: High glycemic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glycemic load meal + placebo capsules
Study: 28917947
Drug: Low glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycemic load meal + placebo capsules
Study: 26335088
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing Therapy
Study: 18454510
Drug: Ribavirin 800
Normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 800 mg/day plus peginterferon alfa‐2a 180 mug/week
Study: 18454510
Drug: Ribavirin 400
Normalized name: ribavirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 400 mg/day plus peginterferon alfa‐2a 180 mug/week
Study: 18454510
Drug: Ribavirin 800
Normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 800 mg/day (group A)
Study: 18454510
Drug: Ribavirin 400
Normalized name: ribavirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 400 mg/day (group B)
Study: 16290907
Drug: peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2b 1.5 microg/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day for 24 weeks
Study: 16290907
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with undetectable serum HCV-RNA at treatment week 4
Study: 8788532
Drug: 5‐HT1a‐receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT1a‐receptor agonist ipsapirone (10 mg)
Study: 6403706
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norethindrone + 35 micrograms ethinyl estradiol
Study: 6403706
Drug: Levonorgestrel-containing preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-containing preparation
Study: 6403706
Drug: Levonorgestrel preparation
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel preparation
Study: 27592805
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg intravenously every 2 weeks)
Study: 28718569
Drug: 10% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% potassium hydroxide aqueous solution applied daily to the lesions twice daily for 6 weeks
Study: 28718569
Drug: Cryotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy with liquid nitrogen, applied weekly for 6 weeks
Study: 22634906
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (500 mg/5 cc) three times a week for 8 weeks
Study: 20361911
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment (ACT) as part of integrated care
Study: 10472698
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg bodyweight ketamine racemate before skin incision and 10 micrograms/kg/min ketamine infusion until peritoneum closure, followed by sodium chloride 0.9% as placebo after final skin suture.
Study: 10472698
Drug: Placebos before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos before skin incision and intraoperatively, followed by 0.5 mg/kg bodyweight ketamine after last skin suture.
Study: 1932765
Drug: buflomedil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: buflomedil (400 mg intravenous perfusion for 4 hours daily for 7 days)
Study: 7044160
Drug: Co-trimoxazole (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (high daily dosage regimens)
Study: 27428397
Drug: Faecal immunochemical
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal immunochemical test (FIT) for nonattendees of reduced-preparation CTC
Study: 27428397
Drug: Faecal immunochemical
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal immunochemical test (FIT) for nonattendees of full-preparation CTC
Study: 25201518
Drug: Single morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single morning dose of mitotane
Study: 25201518
Drug: No morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: No morning dose of mitotane
Study: 22379738
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 350 mg daily for 1 month (n = 5)
Study: 20569710
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone/10 microg ethinyl estradiol
Study: 17038829
Drug: YF‐VAX (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF‐VAX (licensed yellow fever 17D vaccine)
Study: 9241098
Drug: BIS 5
Normalized name: RIXUBIS 500units Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 5 mg
Study: 9241098
Drug: BIS 10
Normalized name: RIXUBIS 1000units Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 10 mg
Study: 8106952
Drug: Periodontal dressing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Study: 8106952
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Study: 3307404
Drug: Weight reduction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction, exercise, diet, and glipizide therapy
Study: 3307404
Drug: Insulin (baseline)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (baseline)
Study: 19423999
Drug: Transdermal microdose
Normalized name: LANCET,MICRODOT SAFETY 28G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal microdose 17beta-estradiol (0.014 mg/d)
Study: 19423999
Drug: Oral raloxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral raloxifene (60 mg/d)
Study: 16919005
Drug: First-line bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line bosentan treatment
Study: 3319646
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg o.d.
Study: 27091318
Drug: NaCl (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (control) 24 mg/kg
Study: 25219389
Drug: Algorithm-based pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based pharmacological treatment
Study: 18274692
Drug: Guideline dissemination,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline dissemination, educational session, plus individualised treatment advice
Study: 11360070
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg daily for 7 days (treated partners)
Study: 8083713
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate at 150 mg/m2/d
Study: 8083713
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (various doses: 50, 75, 100, 125, 150, 175, and 200 mg/m2/d)
Study: 2587982
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol spray
Study: 1234503
Drug: Chlordiazepoxide hydrochloride
Normalized name: Chlordiazepoxide Hydrochloride
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlordiazepoxide hydrochloride (20 mg)
Study: 31422111
Drug: CA125-guided diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA125-guided diuretic treatment
Study: 25933495
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (HF; 46 g fat, 1210 kcal)
Study: 25933495
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (LF; 15 g fat, 1214 kcal)
Study: 24468780
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of eravacycline/kg intravenously every 12 h for a total of seven doses over 4 days
Study: 17489325
Drug: Triptorelin (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (monthly injection, group 1; n = 40)
Study: 15278236
Drug: Operative or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative or conservative therapies in sentinel node-positive patients
Study: 11309436
Drug: Optimized-treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized-treatment arm (40 mg mitomycin C with pharmacokinetic manipulations and urine alkalinization)
Study: 11309436
Drug: Standard-treatment arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-treatment arm (20 mg mitomycin C without pharmacokinetic manipulations or urine alkalinization)
Study: 2023746
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid (Amicar) 50 mg/kg every 4 hours for 5 days (max 30 g daily)
Study: 2023746
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg daily (adjusted for weight) in two divided doses
Study: 6452796
Drug: Nomifensine (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (large doses)
Study: 6452796
Drug: Zimelidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (75 mg)
Study: 6452796
Drug: Zimelidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (150 mg)
Study: 28848225
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide supplementation (up to a maximum of 3 times 450 mg daily)
Study: 11133624
Drug: 0.078 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.078 microg/mL sufentanil
Study: 11133624
Drug: 0.156 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.156 microg/mL sufentanil
Study: 11133624
Drug: 0.312 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.312 microg/mL sufentanil
Study: 11133624
Drug: 0.468 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.468 microg/mL sufentanil
Study: 8021737
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (VP-16) at 50 mg/m2
Study: 8021737
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (VP-16) at 60 mg/m2
Study: 8021737
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (VP-16) at 75 mg/m2
Study: 2915763
Drug: L-carnitine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine therapy (1 g i.v.) at the end of dialysis for 1 month, followed by L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2) for 3 months
Study: 2915763
Drug: L-carnitine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine added to the dialysate (2 g in group 1, 4 g in group 2)
Study: 2915763
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of L-carnitine (2 g)
Study: 28526046
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon angioplasty with or without bail-out bare metal stenting
Study: 28526046
Drug: Primary stenting
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary stenting with drug-eluting stents
Study: 25623382
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment (L group)
Study: 23010700
Drug: 10% sucralfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucralfate ointment
Study: 21169874
Drug: Lacto‐Wolfberry (LWB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacto‐Wolfberry (LWB) 13.7 g/d for 90 days
Study: 9177507
Drug: Acid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid infusion (0.1 N HCl at 6-8 cc/min)
Study: 9177507
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (0.9 N saline)
Study: 2859047
Drug: Ro31-1118 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro31-1118 (10 mg orally)
Study: 2859047
Drug: Ro31-1118 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro31-1118 (20 mg orally and intravenously)
Study: 2859047
Drug: Ro31-1118 (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro31-1118 (40, 80, 160, and 320 mg orally)
Study: 2859047
Drug: Ro31-1118 (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro31-1118 (320 mg)
Study: 2859047
Drug: Ro31-1118 (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro31-1118 (not specified dose)
Study: 26956551
Drug: Testosterone pretreatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone pretreatment (10 mg transdermal gel for 21 days)
Study: 23152846
Drug: Ginger preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger preparation
Study: 20186829
Drug: High-dose ghrelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ghrelin (13 microg/kg daily)
Study: 20186829
Drug: Low-dose ghrelin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ghrelin (0.7 microg/kg daily)
Study: 17595201
Drug: Oral Amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Amoxicillin
Study: 16327738
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of the EORTC QLQ-SAT32 questionnaire
Study: 16327738
Drug: Interview administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview administration of the EORTC QLQ-SAT32 questionnaire
Study: 11926620
Drug: Grapeseed extract
Normalized name: Radiance Grapeseed Extract 100mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapeseed extract (GSE) 100 mg, twice daily
Study: 7653811
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine (1 mg/kg)
Study: 28719078
Drug: Luseogliflozin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (2.5 mg, newly administered)
Study: 28719078
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg, newly or additionally administrated)
Study: 24908387
Drug: Voluntary transition
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voluntary transition to oral methadone
Study: 23652909
Drug: Isotretinoin 20
Normalized name: isotretinoin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 20 mg orally once daily for 3 months
Study: 23652909
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (glucose capsules) for 3 months after isotretinoin therapy